Estramustine phosphate in the treatment of hormone escape prostatic carcinoma - a 3 year follow-up

Estramustine phosphate in the treatment of hormone escape prostatic carcinoma - a 3 year follow-up

Objective: A recent literature review has shown rekin-dled interest in the use of estramustine phosphate (EMP) inpatients with advanced prostatic cancer. This led us to assess prostate specific antigen (PSA ) response and drug tolerability following EMP therapy inpatients with hor-mone refractory p...

Full description

Bibliographic Details
Main Authors:	Altaf H Syed, Mohd N Akhtar, C Shearing, P R Bollina, D N Tulloch
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2003-01-01
Series:	Indian Journal of Urology
Subjects:	Estramustine phosphate. prostate specific antigen. advanced prostate cancer bone pain side effects/toxicity.
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=129;epage=134;aulast=Syed

Similar Items

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
by: Narita Shintaro, et al.
Published: (2012-01-01)

Estramustine-Induced Suicidal Erythrocyte Death
by: Rosi Bissinger, et al.
Published: (2013-11-01)

Chemotherapy for hormone-resistant prostate cancer: Where are we today?
by: Tomas Buchler, et al.
Published: (2007-01-01)

Lysophosphatidic Acid Modifies the Response of PC3 Prostate Cancer Cells to Chemotherapeutics
by: G. Esra Genc, et al.
Published: (2020-09-01)

Efficacy of switching therapy of luteinizing hormone–releasing hormone analogue for advanced prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-11-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients
by: Antonio B. Porcaro, et al.

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
by: Bai X, et al.
Published: (2020-08-01)

Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma
by: Daoyuan Wang, et al.
Published: (2015-01-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Association of prostate volume with incidence and aggressiveness of prostate cancer
by: Al-Khalil S, et al.
Published: (2016-10-01)

Is It Effective to Perform Two More Prostate Biopsies According to Prostate-Specific Antigen Level and Prostate Volume in Detecting Prostate Cancer? Prospective Study of 10-Core and 12-Core Prostate Biopsy
by: Byung Il Yoon, et al.
Published: (2012-05-01)

Moving ahead of prostate-specific antigen
by: Banyameen Mohamad Iqbal, et al.
Published: (2016-01-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01)

BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01)

The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen
by: Ahmet Ali Sancaktutar, et al.
Published: (2012-06-01)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?
by: Hasan Deliktaş, et al.
Published: (2017-06-01)

PROSTATE SPECIFIC ANTIGEN LEVEL FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE
by: Johannes Aritonang, et al.
Published: (2020-01-01)

Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH)
by: Aulia Nur Fadila, et al.
Published: (2020-07-01)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
by: Yasuhide Kitagawa, et al.
Published: (2015-06-01)

The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen
by: Hee Ju Cho, et al.
Published: (2014-12-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
by: Myungsun Shim, et al.
Published: (2019-07-01)

Study of prostatic pathology and its correlation with prostate specific antigen level
by: S Hirachand, et al.
Published: (2017-03-01)

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade
by: Vojinov Saša, et al.
Published: (2011-01-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

Efficacy of Prostate-Specific Antigen to Categorize Men with Prostate Pathology into Benign, Premalignant, and Malignant Lesions
by: Raja Parthiban, et al.
Published: (2016-06-01)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1
by: Rui Chen, et al.
Published: (2015-01-01)

THE INCIDENCE AND CORRELATION OF CHRONIC PROSTATITIS WITH PSA IN BPH PATIENT
by: Daniel Mahendra Krisna, et al.
Published: (2018-07-01)

Incidence of histological prostatitis and its correlation with PSA density
by: Affonso Celso Piovesan, et al.
Published: (2009-11-01)

Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination
by: Farhad Tadayon, et al.
Published: (2016-01-01)

Beyond prostate-specific antigen: alternatives for prostate neoplasm screening
by: Yu, Kevin Kuo-Han
Published: (2016)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
by: Jeremy YC Teoh, et al.
Published: (2017-01-01)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO AS PREDICTOR FOR PROSTATE CARCINOMA
by: Sajjad Ahmad, et al.
Published: (2017-08-01)

Advanced prostatic carcinomas with low serum levels of prostate-specific antigen
by: Cerović Snežana J., et al.
Published: (2002-01-01)

Cannot write session to /tmp/vufind_sessions/sess_vfthaf4qu731s7rc027rf3aaup